Strides acquires identified ANDAs from Nostrum Laboratories, Inc., USA

Strides Pharma Inc., a Step-down Whollyowned Subsidiary of the Company in the US, has acquired Four approved ANDAs for the US Market from Nostrum Laboratories, Inc., USA.

The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy.

The cumulative market size for the acquired portfolio is ~USD 57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is USD 2.075 million (~INR 176 million).

Two (out of the Four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products.

Shares of Strides Pharma Science Limited was last trading in BSE at Rs. 652.55 as compared to the previous close of Rs. 663.20. The total number of shares traded during the day was 4879 in over 652 trades.

The stock hit an intraday high of Rs. 671.90 and intraday low of 648.20. The net turnover during the day was Rs. 3225054.00.

Source : Equity Bulls

Keywords

StridesPharmaScience INE939A01011 Pharmaceuticals Acquisition ANDAs NostrumLaboratoriesInc USA